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In the March 2011 issue of the Journal of Vascular Surgery, the article by Rzeznik et al (Rzeznik D, Przewlocki T,
Kablak-Ziembicka A, Kozanecki A, Roslawiecka A, Lach J, Tracz W, Podolec P. Effect of renal artery revasculariza-
tion on left ventricular hypertrophy, diastolic function, blood pressure, and the one-year outcome. J Vasc Surg
2011;53:692-7) incorrectly used the abbreviation “RAS” in several locations. The correct usage of the term is as
follows:
In the “Objective” section of the abstract of page 692:
The study aimed to determine the potential interrelations between left ventricle mass (LVM), LV diastolic function,
systolic blood pressure (SBP) and diastolic blood pressure (DBP) and cardiovascular events in patients undergoing renal
artery stenting (RAS).
In the “Background” section of page 692:
Renal artery stenosis occurs in 5% of subjects with hypertension, and it is more frequently encountered in patients with
atherosclerotic lesions in coronary, lower limb, or supraaortic arteries.1-5
A significant renal artery stenosis may lead to activation of the reninangiotensin-aldosterone system and may result in
hypertension and left ventricular hypertrophy.6 Several neurohormonalmechanisms of this action are postulated.7,8 Renal
artery stenosis is associated with progressive renal dysfunction and the increased cardiovascular events rate.9 Furthermore,
left ventricular (LV) hypertrophy has a negative impact on survival and it is an independent risk factor of cardiovascular
events, including cardiovascular death and myocardial infarction.7,10
There are many conflicting data on the impact of renal artery stenting (RAS) on blood pressure control.11,12 In the
observational clinical series, blood pressure was reduced in about two-thirds of patients who underwent RAS procedure;
however, the results of randomized trials are negative or indicate only a borderline/mild impact of RAS procedure on
blood pressure.13Also, there is little data onwhetherRASmay lead to left ventricular hypertrophy reduction.14,15 The other
interesting issue is whether reduced diastolic function, commonly present in hypertensive patients, may be influenced by the
RAS procedure, and whether this action may be associated with blood pressure values.16
The present study aimed to determine whether stenting of renal artery stenosis may lead to regression of LV hypertrophy and
improvement in the LV diastolic function. Also, the study aimed to assess the interrelation between potential changes in LV
mass and diastolic function and blood pressure.We sought for predictors of cardiovascular (CV) events at 1 year following
RAS procedure.
In first two paragraphs of the “Invasive procedure” section of page 693:
Medical treatment prior to and after renal artery stenting (RAS) was recorded and analyzed.
Eligibility criteria were determined on the basis of published guidelines for percutaneous revascularization of the renal
artery stenosis.1 In brief, the decision to perform RAS was reached based on the clinical assessment, evaluated renal
function or drug-resistant or malignant hypertension, and the grade of RAS stenosis exceeding 60% lumen reduction. The
main indication for RAS procedure was ill-controlled arterial hypertension in 41 (48.8%) patients (despite administra-
tion of at least three antihypertensive medications, including at least one diuretic), pulmonary flash edema in five (5.9%)
patients, and progressive renal failure in 47 (55.9%) patients. Thus, in nine patients more than one indication for RAS
was met.286
